PMCB (PharmaCyte Biotech) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 09, 2026)


PMCB PharmaCyte Biotech Inc PMCB
30 GF Score
Price $0.71
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech 5-Year Yield-on-Cost %?

PharmaCyte Biotech PMCB -2.26% 30 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus rates PMCB with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 153 Biotechnology companies, PharmaCyte Biotech ranks worse than 653594.12% on this metric.

PharmaCyte Biotech's yield on cost for the quarter that ended in Jan. 2026 was 0.00.


The historical rank and industry rank for PharmaCyte Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:



PMCB's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.66
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

PharmaCyte Biotech  (NAS:PMCB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


PharmaCyte Biotech 5-Year Yield-on-Cost % Related Terms


PMCB vs ERNA, SYBX, ASBP: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's 5-Year Yield-on-Cost % falls into.


PMCB
30GF Score
PharmaCyte Biotech Inc PMCB
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of PharmaCyte Biotech is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
PharmaCyte Biotech (PMCB) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #999999 out of 153 companies in the Biotechnology industry.
Is PharmaCyte Biotech's 5-Year Yield-on-Cost % too high?
PharmaCyte Biotech's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, PharmaCyte Biotech ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's 5-Year Yield-on-Cost % compare to ERNA and SYBX?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places PharmaCyte Biotech in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. PharmaCyte Biotech's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
30GF Score

Get the complete analysis for PMCB

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price